Low risk — use of or exposure to this product is not likely to cause adverse health consequences.
Mozobil (plerixafor injection) 24 mg/1.2 mL (20 mg/mL) per vial Recalled by Genzyme Corporation / Genzyme Biosurgery Due to Labeling: Incorrect or Missing Lot and/or Exp. Date
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Genzyme Corporation / Genzyme Biosurgery directly.
Affected Products
Mozobil (plerixafor injection) 24 mg/1.2 mL (20 mg/mL) per vial, Rx Only, For Subcutaneous Injection only, Manufactured by: Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142 A Sanofi Company Country of Origin : United Kingdom, NDC 0024-5862-01
Quantity: 9,530 vials
Why Was This Recalled?
Labeling: Incorrect or Missing Lot and/or Exp. Date
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About Genzyme Corporation / Genzyme Biosurgery
Genzyme Corporation / Genzyme Biosurgery has 2 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report